Cargando…

Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Dogs

Canine vaccination is the main tool for preventing dangerous and widespread diseases. The strongly recommended (core) dog vaccines are against Canine Parvovirus type 2 (CPV-2), Canine Distemper Virus (CDV), and Canine Adenovirus (CAdV-1), but vaccination protocols should be tailored to dog lifestyle...

Descripción completa

Detalles Bibliográficos
Autores principales: Dall’Ara, Paola, Lauzi, Stefania, Zambarbieri, Jari, Servida, Francesco, Barbieri, Laura, Rosenthal, Roberto, Turin, Lauretta, Scarparo, Elena, Filipe, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961557/
https://www.ncbi.nlm.nih.gov/pubmed/36836944
http://dx.doi.org/10.3390/life13020587
_version_ 1784895784182874112
author Dall’Ara, Paola
Lauzi, Stefania
Zambarbieri, Jari
Servida, Francesco
Barbieri, Laura
Rosenthal, Roberto
Turin, Lauretta
Scarparo, Elena
Filipe, Joel
author_facet Dall’Ara, Paola
Lauzi, Stefania
Zambarbieri, Jari
Servida, Francesco
Barbieri, Laura
Rosenthal, Roberto
Turin, Lauretta
Scarparo, Elena
Filipe, Joel
author_sort Dall’Ara, Paola
collection PubMed
description Canine vaccination is the main tool for preventing dangerous and widespread diseases. The strongly recommended (core) dog vaccines are against Canine Parvovirus type 2 (CPV-2), Canine Distemper Virus (CDV), and Canine Adenovirus (CAdV-1), but vaccination protocols should be tailored to dog lifestyles. Vaccination guidelines suggest vaccinating adult dogs no more frequently than every 3 years using modified live (attenuated) vaccines (MLV), thus obtaining a long-lasting (sometimes throughout life) specific protection in many but not all animals. The aim of this study was to determine the actual levels of seroprotection against CPV-2, CDV and CAdV-1 in a cohort of Italian dogs by using the in-practice test VacciCheck. A total of 1,027 dogs (951 vaccinated and 76 unvaccinated) were analyzed for Protective Antibody Titers (PATs) against CPV-2, CDV, and CAdV-1. Differences related to sex, age, breed size, health status, and time elapsed since last vaccination were evaluated. Half of the entire canine cohort (50.6%) had PATs for all three viruses (68.5% considering only vaccinated dogs). In particular, 90.8% of dogs were protected against CPV-2, 68.6% against CDV, and 79.8% against CAdV-1. Most dogs remained protected for 3 years after vaccination or longer. Revaccination on a 3-year basis can then be recommended for core MLV vaccines without altering individual’s seroprotection or even herd immunity.
format Online
Article
Text
id pubmed-9961557
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99615572023-02-26 Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Dogs Dall’Ara, Paola Lauzi, Stefania Zambarbieri, Jari Servida, Francesco Barbieri, Laura Rosenthal, Roberto Turin, Lauretta Scarparo, Elena Filipe, Joel Life (Basel) Article Canine vaccination is the main tool for preventing dangerous and widespread diseases. The strongly recommended (core) dog vaccines are against Canine Parvovirus type 2 (CPV-2), Canine Distemper Virus (CDV), and Canine Adenovirus (CAdV-1), but vaccination protocols should be tailored to dog lifestyles. Vaccination guidelines suggest vaccinating adult dogs no more frequently than every 3 years using modified live (attenuated) vaccines (MLV), thus obtaining a long-lasting (sometimes throughout life) specific protection in many but not all animals. The aim of this study was to determine the actual levels of seroprotection against CPV-2, CDV and CAdV-1 in a cohort of Italian dogs by using the in-practice test VacciCheck. A total of 1,027 dogs (951 vaccinated and 76 unvaccinated) were analyzed for Protective Antibody Titers (PATs) against CPV-2, CDV, and CAdV-1. Differences related to sex, age, breed size, health status, and time elapsed since last vaccination were evaluated. Half of the entire canine cohort (50.6%) had PATs for all three viruses (68.5% considering only vaccinated dogs). In particular, 90.8% of dogs were protected against CPV-2, 68.6% against CDV, and 79.8% against CAdV-1. Most dogs remained protected for 3 years after vaccination or longer. Revaccination on a 3-year basis can then be recommended for core MLV vaccines without altering individual’s seroprotection or even herd immunity. MDPI 2023-02-20 /pmc/articles/PMC9961557/ /pubmed/36836944 http://dx.doi.org/10.3390/life13020587 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dall’Ara, Paola
Lauzi, Stefania
Zambarbieri, Jari
Servida, Francesco
Barbieri, Laura
Rosenthal, Roberto
Turin, Lauretta
Scarparo, Elena
Filipe, Joel
Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Dogs
title Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Dogs
title_full Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Dogs
title_fullStr Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Dogs
title_full_unstemmed Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Dogs
title_short Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Dogs
title_sort prevalence of serum antibody titers against core vaccine antigens in italian dogs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961557/
https://www.ncbi.nlm.nih.gov/pubmed/36836944
http://dx.doi.org/10.3390/life13020587
work_keys_str_mv AT dallarapaola prevalenceofserumantibodytitersagainstcorevaccineantigensinitaliandogs
AT lauzistefania prevalenceofserumantibodytitersagainstcorevaccineantigensinitaliandogs
AT zambarbierijari prevalenceofserumantibodytitersagainstcorevaccineantigensinitaliandogs
AT servidafrancesco prevalenceofserumantibodytitersagainstcorevaccineantigensinitaliandogs
AT barbierilaura prevalenceofserumantibodytitersagainstcorevaccineantigensinitaliandogs
AT rosenthalroberto prevalenceofserumantibodytitersagainstcorevaccineantigensinitaliandogs
AT turinlauretta prevalenceofserumantibodytitersagainstcorevaccineantigensinitaliandogs
AT scarparoelena prevalenceofserumantibodytitersagainstcorevaccineantigensinitaliandogs
AT filipejoel prevalenceofserumantibodytitersagainstcorevaccineantigensinitaliandogs